Title: Harvey J Brandwein: Innovator in Biologic Manufacturing
Introduction
Harvey J Brandwein is a notable inventor based in the United States, recognized for his contributions to the field of biologic manufacturing. He has developed a highly efficient method for producing primary cell derived biologics, which has significant implications for medical and therapeutic applications.
Latest Patents
Although Harvey J Brandwein currently holds no patents, his innovative work includes a detailed process for creating primary cell derived biologics. This process involves purifying mononuclear cells (MNCs) using an automated cell processor to eliminate contaminating cells. The method includes loading leukocytes onto lymphocyte separation medium (LSM) and centrifuging to obtain purified MNCs. The MNCs are then stored in a closed sterile bag system and stimulated with an induction mixture containing phytohemagglutinin (PHA) or other mitogens, along with ciprofloxacin, in a scalable cell culture device. The resulting biologic is clarified and purified through various filtration and chromatography techniques, ensuring a contamination-free product.
Career Highlights
Harvey J Brandwein is currently associated with Irx Therapeutics, Inc., where he continues to advance his research and development efforts in biologic manufacturing. His work emphasizes the importance of automated methods for cell purification and scalable induction processes, which are crucial for the production of high-quality biologics.
Collaborations
Harvey collaborates with George J Fennington, contributing to the innovative environment at Irx Therapeutics, Inc. Their combined expertise enhances the potential for breakthroughs in biologic manufacturing.
Conclusion
Harvey J Brandwein's innovative approach to primary cell derived biologics positions him as a significant figure in the field of biologic manufacturing. His work not only showcases his technical skills but also highlights the importance of automation and scalability in modern medical applications.